Home › Ovarian Epithelial Carcinoma › Minnesota
Ovarian Epithelial Carcinoma clinical trials in Minnesota
7 studies for Ovarian Epithelial Carcinoma are looking for participants at sites in Minnesota.
Cities in Minnesota
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- University of Minnesota - Minneapolis /ID# 275718, Minneapolis
- Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 274780, Saint Louis Park
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT06890338Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Masonic Cancer Center, University of Minnesota, Minneapolis
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 15, 2026 · NCT06915025ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Mayo Clinic (Rochester), Rochester
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, Minneapolis
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 21, 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Minnesota Oncology Hematology PA, Minneapolis
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 2, 2026 · NCT06819007A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Mayo Clinic, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT06395519CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- SCRI - Minnesota Oncology Hematology, P.A., Minneapolis
- University of Minnesota, Minneapolis
- Mayo Clinic, Rochester
RecruitingPhase 2
Ages 18 and older · Women · Updated Dec 23, 2025 · NCT06690775From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.